{"schema_version":"secwatch.filing_event.v1","accession":"0001860782-24-000048","form_type":"8-K","ticker":null,"cik":"0001860782","company_name":"2seventy bio, Inc.","filed_at":"2024-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.945375+00:00","generated_at":"2026-06-04T04:58:34.469247+00:00","sec_items":["2.01","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"2seventy bio closes sale of oncology/autoimmune pipeline to Regeneron; focuses on Abecma","bullets":["Sold oncology/autoimmune R&D programs and clinical manufacturing to Regeneron for $5M upfront; eligible for $10M milestone and royalties.","Approximately 160 employees hired by Regeneron; 2seventy now ~65 employees, exclusively focused on Abecma commercialization with BMS.","Pro forma net loss for 2023 adjusted from $217.6M to $135.5M; cash runway extended beyond 2027.","Amended transition agreement with ex-CEO Nick Leschly clarifies eligibility for benefit plans as Chairman."],"urls":{"canonical":"https://secwatch.observer/filing/0001860782-24-000048","json":"https://secwatch.observer/filing/0001860782-24-000048.json","markdown":"https://secwatch.observer/filing/0001860782-24-000048.md","text":"https://secwatch.observer/filing/0001860782-24-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860782/000186078224000048/0001860782-24-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860782/000186078224000048/tvst-20240329.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T04:58:34.469247+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8fd143a7a74e196b05752905a280eacfbf16c0c2","claim":"2seventy bio, Inc. completed a disposition involving Regeneron Pharmaceuticals, Inc. for $5 million in cash (closed 2024-04-01).","evidence_excerpt":"On April 1, 2024, the Company completed the transactions contemplated by the Asset Purchase Agreement (the “Asset Sale”) and Regeneron paid the Company $5 million in cash and assumed certain related liabilities.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860782/000186078224000048/0001860782-24-000048-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"Regeneron Pharmaceuticals, Inc."},{"label":"Consideration","value":"$5 million in cash"},{"label":"Closing","value":"2024-04-01"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}